Effects of combined aerobic-resistance exercise training on levels of Asprosin, CTRP1, and MG53 in men with diabetes

Investigating the effects of combined aerobic-resistance exercise training on levels of Asprosin, CTRP1, and MG53 in men with type 2 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181006041252N15

Enrollment

Registered

2019-10-25

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: The training group will undergo combined aerobic-resistance exercise training with distinct intensity for 12 weeks, three sessions a week. Each training session wil

Eligibility

Sex/Gender

Male

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Lack of cardiovascular, musculoskeletal, and metabolic disorders limiting exercise Lack of high blood pressure Lack of regular exercise activity in the last 6 months Not receiving insulin No smoking Not having diabetic foot ulcers

Exclusion criteria

Exclusion criteria: Inability to perform exercises

Design outcomes

Primary

Measure	Time frame
Determine the levels of Asprosin. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.;Determine the levels of CTRP1. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.;Determine the levels of MG53. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.	—

Measure

Time frame

Determine the levels of Asprosin. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.;Determine the levels of CTRP1. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.;Determine the levels of MG53. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the start of the training program. Method of measurement: Use of Luminescence quantitative and ELISA methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Zarei

Sabzevar University of Medical Sciences

Zarei.m8716@yahoo.com+98 51 4401 1604

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026